Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
While the medication starts working as soon as its administered, significant appetite reduction usually takes a few days to weeks
They might not add the preservatives in the same way that a retail manufacturer would
Efficacy Results of a SURPASS open-label, phase III trial, published in 2021, demonstrated tirzepatides superior glycaemic efficacy and weight reduction compared with existing GLP-1 receptor agonists, including semaglutide 6
No, semaglutide is not approved for an every other week dosing schedule